1. Home
  2. EXC vs TAK Comparison

EXC vs TAK Comparison

Compare EXC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXC
  • TAK
  • Stock Information
  • Founded
  • EXC 1999
  • TAK 1781
  • Country
  • EXC United States
  • TAK Japan
  • Employees
  • EXC N/A
  • TAK N/A
  • Industry
  • EXC Power Generation
  • TAK Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXC Utilities
  • TAK Health Care
  • Exchange
  • EXC Nasdaq
  • TAK Nasdaq
  • Market Cap
  • EXC 45.5B
  • TAK 47.3B
  • IPO Year
  • EXC N/A
  • TAK N/A
  • Fundamental
  • Price
  • EXC $42.73
  • TAK $15.13
  • Analyst Decision
  • EXC Buy
  • TAK
  • Analyst Count
  • EXC 12
  • TAK 0
  • Target Price
  • EXC $46.75
  • TAK N/A
  • AVG Volume (30 Days)
  • EXC 5.1M
  • TAK 3.0M
  • Earning Date
  • EXC 10-29-2025
  • TAK 10-30-2025
  • Dividend Yield
  • EXC 3.73%
  • TAK 3.59%
  • EPS Growth
  • EXC 8.94
  • TAK N/A
  • EPS
  • EXC 2.64
  • TAK 0.59
  • Revenue
  • EXC $23,766,000,000.00
  • TAK $31,053,301,865.00
  • Revenue This Year
  • EXC $5.45
  • TAK $0.40
  • Revenue Next Year
  • EXC $2.90
  • TAK $0.83
  • P/E Ratio
  • EXC $16.28
  • TAK $25.60
  • Revenue Growth
  • EXC 4.47
  • TAK 1.52
  • 52 Week Low
  • EXC $35.94
  • TAK $12.80
  • 52 Week High
  • EXC $48.11
  • TAK $15.69
  • Technical
  • Relative Strength Index (RSI)
  • EXC 35.97
  • TAK 52.51
  • Support Level
  • EXC $42.75
  • TAK $14.87
  • Resistance Level
  • EXC $43.67
  • TAK $15.38
  • Average True Range (ATR)
  • EXC 0.58
  • TAK 0.18
  • MACD
  • EXC -0.08
  • TAK -0.03
  • Stochastic Oscillator
  • EXC 1.38
  • TAK 38.46

About EXC Exelon Corporation

Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.

About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Share on Social Networks: